On Friday, Praxis Precision Medicines, Inc. PRAX launched interim knowledge from Research 1 of the Essential3 program of ulixacaltamide in important tremor (ET).
The Impartial Knowledge Monitoring Committee (IDMC) really helpful stopping the research for futility. The outcomes are unlikely to satisfy the first efficacy endpoint.
The committee additionally indicated that some underlying statistical mannequin assumptions might need influenced this final result and inspired Praxis to discover different evaluation strategies.
Additionally Learn: Praxis Precision Medicines Touts Encouraging Knowledge For Mid-Stage Epilepsy Drug
Given the superior enrollment standing for each Research 1 and Research 2 within the Essential3 program and recommendation obtained by the IDMC, Praxis has determined to finish each research, with topline outcomes anticipated within the third quarter of 2025.
The choice about whether or not the info helps the submission of an NDA will likely be made after analyzing the ultimate outcomes for Research 1 and Research 2.
As of December 31, 2024, Praxis had $469.5 million in money, money equivalents and marketable securities, which is anticipated to fund operations into 2028.
Praxis incurred a internet lack of $58.7 million for the fourth quarter of 2024 in comparison with $26.9 million for the fourth quarter of 2023.
Analyst Reactions:
- HC Wainwright analyst maintains Praxis Precision Medication with a Purchase, decreasing the value goal from $120 to $105.
- Needham analyst maintains Praxis Precision Medication with a Purchase, decreasing the value goal from $150 to $85.
- Baird analyst maintains Praxis Precision Medication with an Outperform, decreasing the value goal from $117 to $73.
- Truist Securities analyst maintains Praxis Precision with a Purchase, decreasing the value goal from $175 to $85.
Value Motion: PRAX inventory is down 4.09% at $37.02 on the final examine Monday.
Learn Subsequent:
Market Information and Knowledge dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
